GLP-1 Compounding Enforcement Actions: Complete FDA Telehealth Warning-Letter Data Through August 1, 2026
By the Weight Loss Provider Guide Editorial Team
GLP-1 Consumer Research — the self-funded, independent research and reference section of Weight Loss Provider Guide. Research pages carry no affiliate links, product recommendations, advertisements, or calls to action.
Last verified: August 1, 2026 · Dataset version 1.0.0 (row-level file dated July 31, 2026)
As of August 1, 2026, the defined 2026 GLP-1 compounding enforcement actions in this tracker consist of 55 published FDA warning letters from two telehealth-marketing waves: 30 letters dated February 20 and announced March 3, and 25 letters dated June 8 and posted June 16. Those 55 letters name 54 unique legal entities, because FitRX, LLC appears in both waves under two consumer-facing brands.
The most common coded pattern is even more concentrated: 51 of 55 letters — 92.7% — contain an example in which FDA said the website obscured who actually compounded the drug or made the telehealth brand appear to be the compounder. That is our editorial coding of the letters, not an FDA category.
A warning letter is not a court judgment. These letters state FDA’s position that the cited representations are false or misleading and cause the products to be misbranded, while giving each recipient an opportunity to respond. FDA also warns that later interaction with a recipient may change the regulatory status of the issues described in its public database.
Now the part that took us longest to find, and the reason this page exists.
Across three letter dates from September 2025 through June 2026, FitRX, LLC appears three times under three different brands: as Zealthy, FitRx, and AM RX. Three letters. Three brands. One legal entity.
That is the whole problem with counting enforcement in this space, and it is why we built a recipient-level dataset instead of writing another summary.
GLP-1 compounding enforcement statistics: the numbers, up front
Letters coded for source or compounder obscuration
51 of 55 — 92.7%
Letters coded for sameness or equivalence claims
34 of 55 — 61.8%
Letters coded for clinical-proof or product-approval claims
13 of 55 — 23.6%
Letters coded for an “FDA-approved” or “FDA-licensed” facility claim
11 of 55 — 20.0%
Letters carrying more than one coded pattern
43 of 55 — 78.2%
FD&C Act sections common to all 55 letters
§§ 502(a), 502(bb), 301(a)
Source: U.S. Food and Drug Administration warning letters. Compiled, deduplicated, and coded by the Weight Loss Provider Guide Editorial Team. Dataset version 1.0.0; row-level file last verified July 31, 2026; page status re-checked August 1, 2026.
The four pattern percentages are our own editorial coding, not FDA categories. Every value is reproducible from the 55 binary-coded rows, and every row links to the corresponding FDA letter.
This dataset shows exactly one thing well: who FDA warned, when, and about what website language or imagery, in the two defined 2026 telehealth-marketing waves. It is complete for that scope, every row links to the original letter, and the coding is reproducible.
It does not establish a court judgment against any named company. It does not establish that a current website still contains the material FDA reviewed. It does not measure product quality, sterility, potency, patient harm, or clinical outcomes. And it deliberately does not count shortage decisions, Federal Register notices, import alerts, recalls, Form FDA 483 observations, facility-quality warning letters, state actions, or private lawsuits.
We separated those on purpose. Mixing unlike actions produces a number that sounds authoritative and means nothing.
How many GLP-1 compounding enforcement actions did FDA take in 2026?
Within this tracker’s defined telehealth-marketing scope, FDA published 55 recipient-specific warning letters in two 2026 waves involving compounded GLP-1 products. Those letters map to 54 unique legal entities because FitRX, LLC received one letter as FitRx in February and a second as AM RX in June. This is not a count of every federal, state, civil, inspectional, manufacturing-quality, or shortage-policy action connected to compounded GLP-1 drugs.
Table 2 — The two defined 2026 telehealth-marketing waves
FDA announced 30 warning letters on March 3, 2026. The individual letters are dated February 20 and concern false or misleading claims involving compounded GLP-1 products offered on recipient websites. The roster includes telehealth, weight-loss, clinic, and related consumer-facing entities; the letters concern labeling, advertising, or promotion rather than facility-inspection findings against the pharmacies that physically made the products.
The June 2026 wave
The second group contains 25 letters dated June 8 and posted to FDA’s site on June 16. All 25 are preserved as separate recipient-level records in the dataset, with legal entity, brand, MARCS-CMS identifier, coding fields, and official source URL.
Why 55 letters is 54 legal entities
FDA addressed one letter to FitRX, LLC dba FitRx (MARCS-CMS 717987) and another to FitRX, LLC dba AM RX (MARCS-CMS 728275). Two letters, two brands, one exact legal-entity name.
We count them as two letters and one entity. Both statements are true and answer different questions. “FDA published 55 letters” is accurate. “FDA warned 55 different companies” is not.
The finding that appears when the frame includes September 2025
The September 2025 letter is outside the 55-row numerator, but it supplies the strongest entity-resolution example in the record.
Table 3 — FitRX, LLC: three FDA letters under three brands
The same legal entity appears in all three headings. That does not establish current noncompliance or a judicial finding. It establishes a narrower and more useful fact: brand-level lists can conceal repeat legal entities unless legal names and DBAs are stored separately.
What claims did FDA challenge in the 55 warning letters?
Under our disclosed coding method, 51 of 55 letters (92.7%) contain a source-or-compounder-obscuration pattern, 34 (61.8%) contain a sameness or equivalence pattern, 13 (23.6%) contain a clinical-proof or product-approval pattern, and 11 (20.0%) contain an “FDA-approved” or “FDA-licensed” facility pattern. The categories are nonexclusive; 43 letters carry more than one.
Every letter in the dataset cites the same three provisions: FD&C Act § 502(a) for false or misleading labeling, § 502(bb) for false or misleading advertising or promotion of a compounded drug, and § 301(a) for introducing or delivering a misbranded drug into interstate commerce. Some letters cite additional provisions, including § 301(c), so those three are described here as the sections common to all 55 — not as a complete list of every section appearing anywhere in the record.
FDA’s own June 2026 telehealth guidance names the same core problem types: branding that implies the telehealth company is the compounder; “generic,” sameness, or approval claims; clinical-proof claims; and claims that a pharmacy or outsourcing facility is FDA-approved or FDA-licensed.
Our four-code framework
Table 4 — Coding framework used in this dataset
Code
Label
A letter receives this code when it contains an example involving…
A
Source or compounder obscuration
Branding, logos, imagery, or label text that FDA says makes the telehealth company appear to be the compounder, or otherwise obscures who produced the drug
B
Sameness or equivalence
“Same active ingredient,” “generic,” “equivalent,” same-result, or materially similar comparison claims involving an FDA-approved drug
C
Clinical proof or product approval
Claims implying that the compounded product itself is clinically proven, FDA-approved, or established as safe or effective
D
“FDA-approved” or “FDA-licensed” facility
Claims that a pharmacy, laboratory, manufacturer, or compounding facility is FDA-approved or FDA-licensed
Source: editorial codebook created from the examples in the 55 FDA warning letters and cross-checked against FDA’s telehealth promotion guidance. These are not official FDA category labels. Codes are nonexclusive.
Table 5 — Coded claim patterns across the 55 letters
Pattern
March (n=30)
June (n=25)
Combined (n=55)
A — Source or compounder obscured
30 (100.0%)
21 (84.0%)
51 (92.7%)
B — Sameness or equivalence
20 (66.7%)
14 (56.0%)
34 (61.8%)
C — Clinical proof or product approval
8 (26.7%)
5 (20.0%)
13 (23.6%)
D — “FDA-approved” or “FDA-licensed” facility
0 (0.0%)
11 (44.0%)
11 (20.0%)
More than one code
24 (80.0%)
19 (76.0%)
43 (78.2%)
Source: all 55 FDA warning letters, coded by Weight Loss Provider Guide under Table 4. Percentages are complete counts of the defined letters, not estimates from a sample. Dataset version 1.0.0.
Code A: the telehealth brand presented as the compounder
The dominant pattern is not merely that a drug was compounded. It is how the source was presented. In letters such as FitRx, OrderlyMeds, NativeMed, and Zeuss, FDA describes product imagery bearing the telehealth brand’s name or logo and says that presentation suggests the brand is the compounder when it is not.
The practical point is simple: the identity of the actual producer cannot be replaced by the marketer’s branding. The FitRx, OrderlyMeds, NativeMed, and Zeuss letters show the pattern directly.
Code B: “same active ingredient,” “generic,” and equivalence claims
FDA treats compounded drugs and approved generics as different categories. A generic drug is approved under the FD&C Act and must meet approval requirements; a compounded drug is not FDA-approved. The letters challenge wording that implies a compounded product is the same as, generic to, or equivalent to an FDA-approved product.
Code C: clinical proof, safety, effectiveness, and product approval
Thirteen letters include language that FDA says presents the compounded product as clinically proven, FDA-approved, or otherwise evaluated for safety and effectiveness. The altRx letter quotes “clinically proven” language; the Maximus letter quotes “clinically studied” and “proven” claims.
The letters separate evidence concerning an FDA-approved drug from claims about the specific compounded preparation being offered. FDA does not review compounded products for safety, effectiveness, or quality before marketing in the way it reviews approved products.
Code D: claims that a pharmacy or facility is FDA-approved or FDA-licensed
Eleven letters challenge claims that a pharmacy or facility was FDA-approved or FDA-licensed. All 11 are in the June wave. Zero are in the February wave.
FDA does not approve or license compounding pharmacies or outsourcing facilities. A facility may register as a section 503B outsourcing facility, but registration is not approval or licensure. The Altru Telehealth letter states that distinction directly.
What changed between the March and June 2026 warning-letter waves?
Source or compounder obscuration remained the dominant coded pattern in both waves — 100% of the February letters and 84% of the June letters. The largest measured difference was the appearance of “FDA-approved” or “FDA-licensed” facility claims in 11 of 25 June letters and none of the 30 February letters, a 44-point difference. This is a comparison of the coded record, not an FDA announcement that its policy changed.
Table 6 — Wave-over-wave change in coded patterns
Pattern
March 2026
June 2026
Percentage-point change
A — Source or compounder obscured
100.0%
84.0%
−16.0
B — Sameness or equivalence
66.7%
56.0%
−10.7
C — Clinical proof or product approval
26.7%
20.0%
−6.7
D — “FDA-approved” or “FDA-licensed” facility
0.0%
44.0%
+44.0
More than one code
80.0%
76.0%
−4.0
Source: all 55 FDA warning letters, coded by Weight Loss Provider Guide. These are complete counts of the defined letters, not a probability sample; no statistical inference is made.
The record establishes the difference. It does not establish why it occurred. The websites may have changed, FDA’s reviewers may have emphasized different examples, or both may be true. The letters alone cannot distinguish among those explanations.
What counts as a GLP-1 compounding enforcement action in this tracker?
The 55-letter total counts recipient-specific FDA warning letters from the two defined 2026 telehealth-marketing waves involving compounded GLP-1 products. Shortage determinations, Federal Register notices, import alerts, recalls, facility inspections, manufacturing-quality letters, state actions, and private litigation are real regulatory events, but they use different legal mechanisms and are excluded from the headline number.
What’s in
A record enters the 55-row dataset when it:
Is a recipient-specific FDA warning letter;
Concerns website labeling, advertising, or promotion of compounded GLP-1 products;
Is dated February 20, 2026 or June 8, 2026; and
Appears on an official FDA warning-letter page.
What’s out
The numerator excludes:
FDA policy statements and drug-shortage determinations;
Enforcement-discretion deadlines;
Federal Register proposals and final determinations;
Import alerts and recalls;
Form FDA 483 inspection observations;
Manufacturing-quality and section 503A or 503B warning letters to pharmacies or outsourcing facilities;
State-board and state-attorney-general actions;
Private manufacturer litigation and court decisions;
Peptide or research-chemical vendor cases; and
The September 2025 warning-letter group.
Why September 2025 needs a separate dataset
The September 2025 material is legally heterogeneous. The GLP-1 Solution letter addresses semaglutide and tirzepatide promotion under §§ 502(a), 502(bb), and 301(a), while also addressing retatrutide under the unapproved-new-drug and adequate-directions provisions in §§ 505(a), 502(f)(1), 301(a), and 301(d).
Adding that mixed letter group to a uniform 2026 telehealth-promotion numerator would make the total larger and the definition worse. A count without a stated numerator is not data. September 2025 belongs in a separately assembled recipient-level dataset with its own scope and codebook.
What does an FDA warning letter actually mean?
These letters state FDA’s position that the cited website representations are false or misleading and cause the promoted products to be misbranded. A warning letter is not a court judgment, criminal conviction, injunction, recall, or shutdown order, and FDA notes that later interaction with a recipient may change the regulatory status of the issues described.
What a warning letter establishes
FDA reviewed identified website content during the period stated in the letter;
FDA’s stated position on the cited language or imagery;
The statutory provisions FDA says are implicated; and
A request for corrective action, supporting information, or an explanation.
What it does not establish
A final judicial determination;
That every issue listed remained unresolved after the response;
That the company stopped operating;
That a current website still contains the historical language;
That a patient was harmed; or
That the product’s sterility, potency, or quality was tested in the website review.
The February FitRx letter asks for a response within 15 working days. The June AM RX letter uses 15 business days. That wording difference is small, but it is why the page does not flatten every letter into one paraphrased deadline.
The historical review date matters too. FitRx says FDA reviewed its site in December 2025; AM RX says March 2026; altRx and Maximus say May 2026. A present-day website is not the same record FDA reviewed. The FDA warning-letter database is the source for the letter and any response or closeout material FDA later posts.
What the 55-letter dataset excludes: manufacturing-quality and section 503B cases
The 55 letters concern website labeling, advertising, or promotion. FDA separately issues inspection-based letters to the pharmacies and outsourcing facilities that physically make compounded drugs. Those records use different evidence, different statutory provisions, and different corrective-action histories, so they are not folded into the telehealth-marketing count.
Table 7 — Two verified 2026 GLP-1 compounding letters excluded from the 55
FDA cited a tirzepatide combination lot that failed sterility testing; semaglutide potency of 79.876%; and tirzepatide potencies of 86.779% and 89.13%. The firm had initiated a voluntary recall on July 9, 2025.
Facility inspection, insanitary conditions, sterility, potency, adulteration, and misbranding — not a telehealth website-promotion letter
FDA said tirzepatide products compounded from bulk API did not qualify for section 503B exemptions because tirzepatide was on neither the 503B Bulks List nor the shortage list at the relevant times. The letter also describes sterility-assurance, CGMP, labeling, and adverse-event-reporting issues.
Inspection-based outsourcing-facility letter addressing section 503B conditions and manufacturing quality
Source: FDA warning letters to Boothwyn Pharmacy, LLC and ProRx LLC. These are examples demonstrating the scope boundary, not a complete count of all excluded actions.
The distinction is not cosmetic. The telehealth letters ask what the website represented. The Boothwyn and ProRx letters ask what the facility made, how it made it, whether the product met strength or sterility expectations, and whether the compounder satisfied the conditions of section 503A or 503B.
Are compounded GLP-1 drugs banned after the shortages ended?
No single statement that “compounded GLP-1s are banned” accurately describes the federal framework. The shortage resolutions ended broad shortage-dependent enforcement-discretion periods, but sections 503A and 503B remain in force with different conditions. FDA’s proposed 2026 determination on semaglutide, tirzepatide, and liraglutide under the 503B Bulks List was still a proposal when this page was checked on August 1, 2026.
Two definitions first, because most confusion starts by collapsing them.
A section 503A compounder is a state-licensed pharmacy, federal facility, or licensed physician compounding for an identified individual patient under the statutory conditions. A section 503B outsourcing facility elects to register with FDA and must satisfy a different set of conditions, including current good manufacturing practice requirements.
Section 503A
FDA’s April 2026 policy page states that a 503A drug must be compounded for an individual patient based on a prescription and that the compounder may not regularly or in inordinate amounts make drugs that are essentially copies of commercially available products.
FDA generally considers a compounded product essentially a copy when it has the same API in the same, similar, or easily substitutable strength and can be used by the same route, unless a prescriber determines and documents that a change produces a significant difference for an identified individual patient. FDA’s current enforcement policy also says it does not intend to act on the “regularly or in inordinate amounts” condition when the compounder fills four or fewer prescriptions of that compounded drug during a calendar month.
Section 503B
An outsourcing facility generally may not compound from a bulk drug substance unless the substance appears on the 503B Bulks List or the drug compounded from that substance appears on FDA’s shortage list at the time of compounding, distribution, and dispensing. FDA’s April 2026 page states that semaglutide and tirzepatide appeared on neither list at that time.
The actual shortage-related enforcement-discretion endpoints
The district court denied the preliminary-injunction motion on March 5, making the later-of condition operative
Semaglutide injection
April 24, 2025
May 22, 2025
The district court denied the preliminary-injunction motion on April 24, which was later than the original April 22 date
Source: FDA’s consolidated GLP-1 compounding policy update. These endpoints concern the enforcement discretion described by FDA for conditions tied to shortage status; they do not suspend other statutory or quality requirements.
The 2026 503B Bulks List proposal — and three official deadlines
On April 30, 2026, FDA announced that it was proposing not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List. The Federal Register notice published May 1 as 91 FR 23431, Docket No. FDA-2018-N-3240.
The comment deadline appears three ways in the official record:
Table 9 — Official dates stated for the 503B Bulks List comment period
Source: FDA’s April 30 announcement, the May 1 Federal Register proposal, and the June 26 extension. The extended July 30 date is the operative deadline.
The comment period closed July 30. The August 1 status check found the proposal and extension, but no final Federal Register determination.
If FDA finalizes the proposal as written and the drugs remain off the shortage list, outsourcing facilities would lack the two section 503B(a)(2)(A)(i) bases for compounding those drugs from bulk substance: inclusion on the 503B Bulks List or presence on the shortage list at compounding, distribution, and dispensing. Section 503A remains a separate patient-specific framework.
What current research shows about the post-shortage compounded GLP-1 market
A peer-reviewed secret-shopper study published July 17, 2026 in JAMA Health Forum documented continued compounded GLP-1 availability after the shortage-related wind-downs. The researchers identified 75 brick-and-mortar weight-loss clinics and medical spas in West Virginia and Oklahoma that offered compounded GLP-1 receptor agonists during fieldwork conducted from August through October 2025.
Table 10 — JAMA Health Forum findings from 75 businesses
Finding
Result
Businesses included
75
States
West Virginia and Oklahoma
Offered compounded semaglutide
69 of 75 — 92.0%
Offered compounded tirzepatide
65 of 75 — 86.7%
Offered oral or sublingual compounded formulations
7 of 75 — 9.3%
Offered a compounded product with any additive
44 of 75 — 58.7%
Offered a compounded product with B vitamins
42 of 75 — 56.0%
Source: DiStefano MJ, et al. “Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand”, JAMA Health Forum, published July 17, 2026. The study used a cross-sectional secret-shopper design in two purposively selected states and does not represent online-only telehealth platforms or the entire United States.
The additive numbers matter because FDA’s April 2026 policy page gives semaglutide combined with vitamin B12 as a specific example that may still be considered essentially a copy when the route and strength criteria are met and no documented patient-specific significant difference applies. Adding B12 is not an automatic escape hatch from the essentially-copy analysis.
The Altru Telehealth letter separately quotes marketing language describing compounded semaglutide combined with a vitamin such as B12, alongside same-result and approval-related claims. The study does not establish that every additive formulation is unlawful, and the warning letter does not decide the legality of every patient-specific prescription. Together, the sources show why “it has B12 added” is not a complete legal or regulatory answer.
Federal GLP-1 compounding timeline, 2024–2026
The 55 warning letters sit inside a wider sequence of shortage decisions, enforcement-discretion endpoints, facility cases, promotional letters, and the pending 503B Bulks List process. The timeline below keeps those mechanisms separate instead of adding them into one total.
Table 11 — Federal context for the 2026 telehealth warning-letter dataset
Date
Event
Type
Counted in the 55?
October 2, 2024
FDA determines the tirzepatide injection shortage is resolved
Shortage determination
No
December 19, 2024
FDA re-evaluates and reaffirms the tirzepatide shortage resolution
Shortage determination
No
February 21, 2025
FDA determines the semaglutide injection shortage is resolved
Shortage determination
No
March 5, 2025
Tirzepatide 503A shortage-related enforcement discretion ends after the court ruling
JAMA Health Forum secret-shopper fieldwork is conducted
Research
No
September 9, 2025
FDA dates a broader, legally mixed group of GLP-1-related warning letters
Warning letters outside this scope
No
January 16, 2026
FDA dates the Boothwyn Pharmacy facility-quality letter; FDA posts it February 10
Facility-quality warning letter
No
February 20, 2026
FDA dates the 30 telehealth-marketing letters
Defined warning-letter wave
Yes
March 3, 2026
FDA announces the 30-letter wave
Announcement
Yes
April 1, 2026
FDA restates post-shortage conditions under sections 503A and 503B
Policy update
No
April 7, 2026
FDA dates the ProRx outsourcing-facility letter
Facility/section 503B warning letter
No
April 30, 2026
FDA announces the proposal not to include three GLP-1 substances on the 503B Bulks List
Proposal
No
May 1, 2026
Federal Register publishes the proposal at 91 FR 23431
Federal Register notice
No
June 8, 2026
FDA dates the 25 additional telehealth-marketing letters
Defined warning-letter wave
Yes
June 15, 2026
FDA publishes its telehealth promotion guidance
Guidance
No
June 16, 2026
FDA posts the 25 letters
Publication of defined wave
Yes
June 26, 2026
FDA extends the 503B proposal comment period to July 30
Federal Register notice
No
July 17, 2026
JAMA Health Forum publishes the two-state secret-shopper study
Research
No
July 30, 2026
Extended 503B comment period closes
Rulemaking milestone
No
August 1, 2026
Status check finds no final Federal Register determination on the three-substance proposal
Current status
No
Source: FDA warning letters and policy pages, the Federal Register, and JAMA Health Forum. Compiled by Weight Loss Provider Guide; status checked August 1, 2026. Rows highlighted in grey are the defined warning-letter waves counted in the 55.
Which companies received FDA warning letters over compounded GLP-1 marketing?
All 55 recipients from the two defined 2026 waves are listed below, split by wave and sorted alphabetically by legal entity. Each row preserves the legal entity as FDA named it, the consumer-facing brand separately, the MARCS-CMS reference number, our claim coding, and a direct link to the official FDA letter.
The legal entity and brand are separate fields on purpose. That separation is what surfaces repeat recipients. A dash in the brand field means FDA addressed the letter to the entity name alone, with no separate DBA in the heading.
March 2026 wave — 30 letters dated February 20, announced March 3
Source: the 30 individual FDA warning-letter pages linked in the table. Compiled and coded by the Weight Loss Provider Guide Editorial Team under the codebook in Table 4.
June 2026 wave — 25 letters dated June 8, posted June 16
Source: the 55 individual FDA warning-letter pages linked above. Compiled and coded by the Weight Loss Provider Guide Editorial Team. Codes are defined in Table 4 and reflect our reading of the examples stated in each letter, not FDA’s own category system. Dataset version 1.0.0; row-level file last verified July 31, 2026.
How we built this dataset
We assembled the dataset from FDA’s recipient-specific warning-letter pages rather than from news summaries. Legal entities and consumer brands were recorded in separate fields, legal names were normalized for deduplication, and each letter was coded across four nonexclusive fields using only examples in that letter. Every row retains its official FDA URL so the count and coding can be reproduced.
Source collection
We worked from the FDA warning-letter database, the March 3 announcement, and the individual letter pages. The two included date clusters are February 20 and June 8, 2026. The page-level status was re-checked on August 1, 2026; the downloadable row-level file remains version 1.0.0, dated July 31, 2026.
Entity normalization
We recorded the legal entity as FDA names it in the letter heading and any DBA or consumer brand in a separate field. For deduplication, legal names were lowercased and stripped of punctuation and spacing. We did not merge separate legal entities merely because they share an address, officer, brand family, or apparent business relationship.
FitRX, LLC is the only exact normalized legal-entity match appearing twice in the two 2026 waves.
Claim coding
Each row was coded under the four-field framework in Table 4. A field receives a 1 only when the letter contains a corresponding example. Codes are nonexclusive, and the examples FDA lists may not exhaust every issue in the letter.
Calculation rules
Letter count = number of recipient rows;
Unique-entity count = number of distinct normalized legal entities;
Pattern count = sum of the relevant binary field;
Combined percentage = pattern count ÷ 55;
Wave percentage = pattern count within a wave ÷ that wave’s row count;
Multiple-code count = number of rows with more than one positive code; and
No row is coded zero until its letter has been reviewed.
Reproducibility
The CSV is the publication file. A reader can reproduce the headline totals by counting rows, distinct normalized legal entities, and the four binary code columns.
This is version 1.0.0, the first row-level release. Corrections that do not change scope increment the patch number. New rows or variables within the same scope increment the minor number. A material scope change — such as adding the September 2025 group, state actions, or a complete facility-quality track — increments the major number.
Limitations
This tracker is narrower than the full GLP-1 compounding regulatory landscape, deliberately.
It counts letters in two defined telehealth-marketing waves, not all enforcement. The 55-letter total excludes the September 2025 group, quality and bulk-substance letters to compounders, import alerts, recalls, inspection findings, state proceedings, and private litigation.
A warning letter is an agency compliance action, not a court judgment. The letters state FDA’s position on cited conduct. FDA notes that later correspondence may change the regulatory status of the issues described. We do not independently determine whether a recipient corrected the cited material, whether its current site differs from the reviewed version, or whether it remains in business. The dataset does not currently track response or closeout letters.
The four claim codes are ours, not FDA’s. They make cross-letter comparison reproducible. They are nonexclusive, summarize stated examples, and do not replace the complete letter text.
The wave comparison is a complete count, not a sample. Percentage-point differences describe these 55 letters and do not predict future enforcement.
The unique-entity count uses exact normalized legal names. DBAs are not counted as separate legal entities, while separate corporations are not merged solely because they share an address, executive, or apparent affiliation.
The dataset does not measure product quality or patient outcomes. It does not measure sterility, potency, adverse events, pharmacy licensure, clinical results, or the total volume of federal and state activity. Absence from the list is not a quality signal. Presence is not proof that a patient was harmed.
The JAMA study is not national prevalence research. It covers 75 brick-and-mortar businesses in two purposively selected states during August–October 2025 and does not represent online-only telehealth platforms or all U.S. businesses.
This page is educational, not medical or legal advice. Patients with questions about a compounded medication should speak with the prescriber or dispensing pharmacist. Companies evaluating compliance should read the primary documents and consult qualified regulatory counsel.
How to cite this page
Page
Weight Loss Provider Guide Editorial Team. “GLP-1 Compounding Enforcement Actions: Complete FDA Telehealth Warning-Letter Data Through August 1, 2026.” GLP-1 Consumer Research, Weight Loss Provider Guide. Dataset version 1.0.0. Last verified August 1, 2026. https://weightlossproviderguide.com/research/glp-1-compounding-enforcement-actions
Dataset
Weight Loss Provider Guide Editorial Team. 2026 FDA Compounded GLP-1 Telehealth Warning-Letter Dataset. Version 1.0.0. GLP-1 Consumer Research, 2026.
Table attribution line
Source: U.S. Food and Drug Administration warning letters. Compiled, deduplicated, and coded by the Weight Loss Provider Guide Editorial Team. Dataset version 1.0.0; row-level file last verified July 31, 2026; page status checked August 1, 2026.
Every MARCS-CMS number in the roster is paired with the corresponding FDA source, so each row and aggregate can be checked against the primary record.
Frequently asked questions about GLP-1 compounding enforcement actions
Did FDA issue 55 warning letters, or warn 55 different companies?
FDA published 55 letters in the two defined 2026 telehealth-marketing waves, and they name 54 unique legal entities. FitRX, LLC received one letter as FitRx in February 2026 and another as AM RX in June 2026. “55 letters” is accurate; “55 different companies” is not.
Which company received the most FDA warning letters?
Within the two 2026 waves, FitRX, LLC is the only repeat legal entity, with two letters. Adding the September 2025 Zealthy letter produces three FDA letters addressed to the same legal entity under three brands between September 2025 and June 2026.
Does an FDA warning letter mean a company was shut down?
No. A warning letter states FDA’s position on the cited conduct and requests corrective action or an explanation. It is not a shutdown order or a court judgment, and FDA notes that later interaction may change the regulatory status of the issues described.
What claims did FDA target most often?
Source or compounder obscuration was the most common coded pattern. It appeared in 51 of the 55 letters, usually through product imagery or labeling that FDA said suggested the telehealth brand was the compounder when it was not.
Are compounded GLP-1 products FDA-approved?
No. FDA does not approve compounded drugs and does not verify their safety, effectiveness, or quality before marketing in the way it reviews FDA-approved drug products.
Did FDA ban all compounded semaglutide and tirzepatide?
No single blanket statement describes the framework accurately. The shortage resolutions ended broad shortage-dependent enforcement-discretion periods, while sections 503A and 503B continue to impose different conditions on patient-specific compounding, essentially copies, bulk substances, and outsourcing facilities.
What is the 503B Bulks List, and has the GLP-1 proposal become final?
The 503B Bulks List identifies bulk drug substances that outsourcing facilities may use under the conditions of section 503B. FDA proposed not to include semaglutide, tirzepatide, or liraglutide; the extended comment period closed July 30, 2026. The August 1, 2026 status check found the proposal and extension, but no final Federal Register determination.
Are the 55 letters against telehealth companies or the compounding pharmacies?
The 55 letters are recipient-specific website-promotion letters to telehealth, weight-loss, clinic, and related consumer-facing entities. FDA separately uses facility inspections, recalls, Form FDA 483 observations, and warning letters for manufacturing-quality and section 503A or 503B issues at pharmacies and outsourcing facilities.
Can I verify a warning letter by visiting the company’s website today?
Not reliably. The letters identify the historical website review FDA relied on. The FitRx letter cites a December 2025 review, AM RX cites March 2026, and altRx and Maximus cite May 2026. A current page may have changed after the review or after the warning letter.
How often is this dataset updated?
This page is date-stamped rather than automatically re-dated. The visible verification date records the most recent completed review of FDA’s warning-letter database, and the dataset version changes only when the row-level records or coding change.
GLP-1 Consumer Research is the self-funded, independent research and reference section of Weight Loss Provider Guide. Research pages carry no affiliate links, product recommendations, advertisements, or calls to action. Weight Loss Provider Guide earns affiliate commissions elsewhere on the site, including from companies named in this dataset. No company was included in, excluded from, or characterized differently because of a commercial relationship; inclusion is determined solely by whether a qualifying public FDA warning letter exists. Nothing on this page is medical or legal advice.
Last verified: August 1, 2026 · Dataset version 1.0.0 (row-level file dated July 31, 2026)